Latest news

Phase II Research Against Covid-19 Launched in France with Debiopharm’s Antiviral Alisporivir

Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform

Debiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award

Debiopharm Launches Trilynx – A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head &…

Debiopharm Honored as a 2020 Swiss Biotech Success Story Winner for Outstanding Achievements over 40 Years

5e Challenge pour la Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop…

Debiopharm’s New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer